Henry d'Abo

Sanderling Management CO LLC (Sanderling Ventures) is a venture capital firm founded in 1979 by Robert G. McNeil. The firm is headquartered in San Mateo, California.

Asteres, Inc. develops secure self-service kiosks for the storage and delivery of prescriptions and consumer products. Its product script center, the prescription pickup kiosk for retail, healthcare and military pharmacies that allows patients to pick up and pay for their prescriptions and other items even when the pharmacy is closed. The company was founded by Linda J. Pinney and John A. Beane in 2003 and is headquartered in San Diego, CA.

ACEA Biosciences, Inc. develops bio-sensor platform based on microelectronic technologies. The firm pioneers in development and commercialization of innovative cell analysis instrumentation for life sciences, and is also engaged in drug discovery and pharmaceutical development. Its xCELLigence impedance-based, label-free, real-time cell analysis systems and NovoCyte benchtop flow cytometers are used in preclinical drug discovery and development, toxicology, safety pharmacology, disease studies, and basic academic research. The company was founded in 2002 and is headquartered in San Diego, CA.

Biotechnology Innovation Organization is the world's biotechnology organization, providing advocacy, business development and communications services for more than 1,200 members worldwide. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology technologies. Corporate members range from entrepreneurial companies developing a first product to Fortune 100 multinationals. also represent state and regional biotech associations, service providers to the industry and academic centers.

CTI Capital, Inc. is a Venture Capital firm, a subsidiary of CTI Capital Groupe, Inc. founded in 1987. CTI Capital, Inc. is headquartered in Montréal.

American Cancer Society, Inc. provides information on cancer occurrence, survival, prevention, early detection, and treatment. The non-profit company is based in Kennesaw, GA and has subsidiaries in the United States. The company's SHES department is an intramural research program with world-renowned epidemiologists and health scientists. The company was founded in 1913 by Candy Arrington. Karen E. Knudsen has been the CEO of the company since 2021.

Boehringer Ingelheim Animal Health USA, Inc. manufactures biological vaccines for animals. The firm specializes in pharmaceuticals for cattle, equine, pet, and swine. The company was founded by Albrecht Boehringer in 1885 and is headquartered in Duluth, GA.

Part of Sun International Ltd., San Francisco Investment SA operates casinos. The company is based in San Francisco De Mostazal, Chile. San Francisco Investment was acquired by Sun International Ltd. on December 01, 2014 for $113.98 million.

The National Pharmaceutical Council operates as a not for profit organization. It specializes in research development, information dissemination, education, and communication of information to patients. The company was founded in 1953 and is headquartered in Washington, DC.

Part of Ypsomed Holding AG, Ypsomed AG is a Swiss company that manufactures injection and infusion systems for self-medication and renowned diabetes. The company is based in Burgdorf, Switzerland.

Therillia Development Co., Inc. operates as a portfolio company of Sanderling Ventures. It develops novel drug candidates of interest to Sanderling and other venture capital investors from preclinical to clinical proof of concept. The company is headquartered in Montreal, Canada.

Precithera, Inc. engages in drug development business. The firm focuses on the design and the development of biological agents for the treatment of orphan diseases. The company was founded by Philippe Crine and Susan Schiavi on May 26, 2016 and is headquartered in Outremont, Canada.

Agent Capital LLC (Agent Capital) is a venture capital firm founded in 2017 by Geeta Vemuri. The firm is headquartered in Waltham, Massachusetts.

Apnimed, Inc. operates as a clinical-stage company. It discovers novel pharmaceutical therapies for sleep apnea and related disorders. The company was founded by Lawrence G. Miller and Luigi Taranto Montemurro in 2017 and is headquartered in Cambridge, MA.

Diazon Pharmaceuticals, Inc. engages in the development of the onco-therapeutic DZ-2384 that targets a proven therapeutic pathway in oncology. The company was founded by Anne Roulston, Gordon Shore and Patrick Harran in 2013 and is headquartered in Montreal, Canada.

Anthos Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company that develops and commercializes innovative therapies for high-risk cardiovascular patients. It offers MAA868, an antibody directed at Factor XI and XIa, key components of the intrinsic coagulation pathway. The company was founded by Paris Panayiotopoulos, Ari Brettman and Jonathan E. Freeman in 2018 and is headquartered in Cambridge, MA.

adMare Bioinnovations engages in the provision of research for its academic and biotech partners. The company was founded in 2011 and is headquartered in Vancouver, Canada.

Find Therapeutics develops therapeutics for inflammatory and fibrotic disease. The company is headquartered in Saint-Laurent, Canada.

Smart Immune SAS is a clinical-stage biotechnology company based in Paris, France. Smart Immune is developing Protcell, a thymus-empowered T cell progenitor therapy platform to re-arm the immune system against cancer and infection, enabling next-generation allogeneic T cell therapies for all. The French company aims to improve outcomes for patients with life-threatening diseases such as high-risk blood cancers and primary immunodeficiencies. Smart Immune has ongoing collaborations with leading institutions in the EU and the US. Smart101 is already in phase I/II clinical trials in the EU and the US, looking at the acceleration of complete immune recovery in patients fighting cancer and infection and undergoing allogeneic hematopoietic stem cell transplantation. Smart Immune is also developing therapies using gene-modified T cell progenitors through its Protcell platform to provide targeted treatments against cancer, like persistent off-the-shelf CAR T cells. The company is headquartered at Biotech Santé. The company was founded in 2017 by Karine Rossignol, Marina Cavazzana, Isabelle André, with Karine Rossignol as the CEO since 2017.

Allyx Therapeutics is an American clinical-stage biotechnology company founded in 2019 by a group of experienced biopharma industry executives, venture capitalists, and scientific experts. The company is based in an undisclosed location and aims to deliver a novel approach to preserve and protect synapses for people living with neurodegenerative diseases. Its lead compound, alx-001, is a first-in-class oral therapy with a unique mechanism of action at mglur5 currently in clinical development in Alzheimer's disease. The company is developing an oral drug that demonstrates reversal of learning and memory deficits due to Alzheimer's disease. The company was founded by Timothy Siegert, Stephen M. Bloch, Paul R. Fonteyne, and Stephen M. Bloch has been the CEO since incorporation.

Revelar Biotherapeutics is a biopharmaceutical company based in Bethesda, MD. Revelar Biotherapeutics, Inc. focuses on developing and commercializing breakthrough therapeutic antibody products to address critical unmet patient needs, particularly in the field of COVID-19 and other therapeutic areas. The company's management team has extensive expertise in clinical development, regulatory affairs, business development, and operations with leading pharmaceutical companies. Revelar was spun out of Twist Bioscience in November 2021 and has the ability to leverage Twist Biopharma's antibody discovery and optimization platform to license additional antibodies for non-COVID targets. The company's therapeutic areas of interest include oncology and infectious diseases. Revelar aims to combine its clinical development and commercialization capabilities with Twist's innovative technology platform and industry and academia collaborations to accelerate the discovery and delivery of transformative antibody therapeutics to meet patients' unmet needs. Revelar was founded by Kevin P. Malobisky, and the CEO is Glenn Marina.

Cellaïon SA is a biotech company located in Mont Saint Guibert, Belgium. Cellaïon aims to restore a favorable environment to reboost the regenerative process of the liver and ensure a second life to the native liver instead of losing it. The Belgian company has a strong IP base issued from their own research and academic research at UCLouvain, developed with the objective to generate new products. Cellaïon's treatment covers the wide spectrum of liver diseases, from the highly life-threatening acute-on-chronic liver-failure (ACLF) and acute alcoholic hepatitis, to intermediate severity acute decompensation of cirrhosis (AD) and progressive chronic liver diseases caused by non-alcoholic steatohepatitis (NASH). The company has built up a series of R&D and collaborative partnerships with both industrial and academic partners, allowing Cellaïon to broaden and accelerate its clinical development. The company was founded by Etienne Marc Sokal, who has been the CEO since incorporation.